Harrow Health, Inc. (HROW)
|52 Week Range||10.06-28.25|
|1y Target Est||-|
|DCF Unlevered||HROW DCF ->|
|DCF Levered||HROW LDCF ->|
|Debt / Equity||773.06%||Strong Buy|
Upgrades & Downgrades
Latest HROW news
Harrow Health's 5-Year Guidance
27 September 2023
Harrow Health has guided to at least $1 billion in revenue by 2027 based on their current portfolio of drugs. The company's deep moat and strong customer relationships make it possible for them to acq...
Harrow Health, Inc. (HROW) Q2 2023 Earnings Call Transcript
9 August 2023
Harrow Health, Inc. (NASDAQ:HROW ) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Execut...
Harrow Health And Its Interesting 11.6% 2027 Baby Bond
1 August 2023
Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 baby bonds, with one looking particularly interestin...
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
20 July 2023
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road...
Why Shares of Harrow Health Are Jumping Wednesday
19 July 2023
Harrow added seven new products through an acquisition. The company said it expects increased revenue year over year in the second quarter.
Harrow Health (HROW) Flat As Market Sinks: What You Should Know
23 June 2023
Harrow Health (HROW) closed at $18.52 in the latest trading session, marking no change from the prior day.
Harrow Health: Mostly Good, Some Bad
12 June 2023
Harrow Healthcare is well-positioned to grow in the US Ophthalmology market, with a branded pharma sales strategy that could boost growth and margins. The company's medium-term earnings outlook is str...
Analysts Initiate Coverage: 5 Stocks for Higher Returns
15 May 2023
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like MicroStrategy (MSTR), SPX Technologies (SPXC), Cvent (CVT), Harrow Health (HROW) and Banco (BM...
Why Shares of Harrow Health Are Slumping Friday
12 May 2023
Harrow had a $6.6 million loss in the first quarter. It just launched its latest therapy, the ocular anesthesia Iheeza.